SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a highly effective and safe new treatment option for adults with moderate-to-severe obesity, beyond current standard-of care metabolic and bariatrics surgery.
This application is based on the encouraging results from the Phase 3 registration clinical study GLORY-2 (NCT06164873) of mazdutide 9 mg in Chinese adults with moderate to severe obesity. The study met its primary endpoints and all key secondary endpoints. [Link]
At Week 60, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed. The mazdutide 9 mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide 9 mg group achieved a weight reduction of 20% or more, versus 2.6% in the placebo group (P